Luca Gianni

Active 1982–2026

140
Papers
55,269
Citations
93
h-index
138
i10-index

Citations

Citations per year for Luca Gianni1971: 1 citations1983: 3 citations1984: 10 citations1985: 13 citations1986: 13 citations1987: 13 citations1988: 11 citations1989: 11 citations1990: 7 citations1991: 2 citations1993: 6 citations1994: 9 citations1995: 14 citations1996: 25 citations1997: 43 citations1998: 57 citations1999: 57 citations2000: 48 citations2001: 74 citations2002: 76 citations2003: 104 citations2004: 115 citations2005: 162 citations2006: 213 citations2007: 219 citations2008: 201 citations2009: 216 citations2010: 258 citations2011: 262 citations2012: 300 citations2013: 404 citations2014: 434 citations2015: 427 citations2016: 457 citations2017: 443 citations2018: 430 citations2019: 1,624 citations2020: 1,738 citations2021: 1,819 citations2022: 1,647 citations2023: 1,410 citations2024: 2,322 citations2025: 1,206 citations2026: 40 citations1972–1982: no citations, so these years are not shown1992: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,942 citing papers, 23.4% of this breakdownChina: 2,892 citing papers, 13.7% of this breakdownItaly: 1,406 citing papers, 6.6% of this breakdownUnited Kingdom: 1,071 citing papers, 5.1% of this breakdownGermany: 1,014 citing papers, 4.8% of this breakdownFrance: 792 citing papers, 3.7% of this breakdownSpain: 760 citing papers, 3.6% of this breakdownCanada: 660 citing papers, 3.1% of this breakdownJapan: 574 citing papers, 2.7% of this breakdownSwitzerland: 520 citing papers, 2.5% of this breakdownNetherlands: 510 citing papers, 2.4% of this breakdownBelgium: 480 citing papers, 2.3% of this breakdown
0%23.4%Other 26.1%

Fields

  • Medicine58.7%
  • Biochemistry, Genetics and Molecular Biology30.7%
  • Immunology and Microbiology2.6%
  • Materials Science2%
  • Engineering1.9%
  • Computer Science1%
  • Other3.1%

Topics

  • HER2/EGFR in Cancer Research8.5%
  • Breast Cancer Treatment Studies7%
  • Cancer Treatment and Pharmacology3.8%
  • Cancer Immunotherapy and Biomarkers3.5%
  • Monoclonal and Polyclonal Antibodies Research3.2%
  • Advanced Breast Cancer Therapies3.2%
  • Other70.8%

Coauthors

All papers

Open in search
  1. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 1,543

  2. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bernd Gerber, Charles E. Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, W. Eiermann, Gϋnter von Minckwitz - The Lancet 2014 cited by 4,710

  3. Treatment landscape of triple-negative breast cancer — expanded options, evolving needs

    Authors: , , , - Nature Reviews Clinical Oncology 2021 cited by 1,331

  4. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

    Authors: , , , , - Nature Reviews Clinical Oncology 2016 cited by 3,072

  5. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

    Authors: , , , , , , , , , , , , , - New England Journal of Medicine 2012 cited by 3,784

  6. HER2-positive breast cancer

    Authors: , - The Lancet 2016 cited by 1,110

  7. Spatial predictors of immunotherapy response in triple-negative breast cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2023 cited by 325

  8. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2011 cited by 2,358

  9. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sunil R. Lakhani, W Janni, Barbro Linderholm, T.-W. Liu, Niklas Loman, Larissa A. Korde, Sibylle Loibl, Peter C. Lucas, Frederik Marmé, E. Martinez de Dueñas, Robin McConnell, Kelly‐Anne Phillips, Martine Piccart, Giovanna Rossi, Rita K. Schmutzler, Elżbieta Senkus, Zhi-Ming Shao, Priyanka Sharma, Christian F. Singer, Tanja Španić, Elmar Stickeler, Masakazu Toi, Tiffany A. Traina, Giuseppe Viale, Gabriele Zoppoli, Y.H. Park, Rinat Yerushalmi, Huan Yang, D. Pang, Kyung Hae Jung, Audrey Mailliez, Zhaoqing Fan, Isabelle Tennevet, J. Zhang, T. Nagy, Gabe S. Sonke, Qiuhong Sun, Marina Parton, Marco Colleoni, Marcus Schmidt, Adam Brufsky, W. Razaq, Bella Kaufman, David Cameron, Christine Campbell, Andrew Tutt, P. Sevelda, Ferdinand Haslbauer, Monika Penzinger, Leopold Öhler, Christoph Tinchon, Richard Greil, Sonja Heibl, Rupert Bartsch, Viktor Wette, Christian F. Singer, Claudia Pasterk, Ruth Helfgott, Gunda Pristauz-Telsnigg, Herbert Stöger, A. Weltermann, Daniel Egle, I. Thiel, David Fuchs, Holger Rumpold, Kathrin Strasser‐Weippl, Beate Rautenberg, Volkmar Müller, Marcus Schmidt, Stefan Paepke and 509 more - Annals of Oncology 2022 cited by 447

  10. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mitch Dowsett, Frances Duane, Vaughan Evans, Marianne Ewertz, Bernard Fisher, John Forbes, Leslie G. Ford, J.-C. Gazet, Richard D. Gelber, Lucy Gettins, Luca Gianni, Michael Gnant, Jon Godwin, Aron Goldhirsch, Pamela J. Goodwin, Richard Gray, Daniel F. Hayes, Catherine Hill, James N. Ingle, Reshma Jagsi, R. Jakesz, Sam James, Wolfgang Janni, Hui Liu, Zulian Liu, Caroline Lohrisch, Sibylle Loibl, Liz MacKinnon, Andreas Makris, Eleftherios P. Mamounas, Gurdeep Mannu, Miguel Martín, S. Mathoulin, L. Mauriac, Paul McGale, Theresa McHugh, Philip Morris, Hirofumi Mukai, Larry Norton, Yasuo Ohashi, Ivo A. Olivotto, Soon Young Paik, Hongchao Pan, Richárd Pető, Martine Piccart, Lori J. Pierce, Philip Poortmans, Trevor J. Powles, K.I. Pritchard, Joseph Ragaz, Vinod Raina, Peter M. Ravdin, Simon Read, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Suzy Scholl, Dennis J. Slamon, Lidija Sölkner, Joseph A. Sparano, Seth M. Steinberg, Rosemary Sutcliffe, Sandra M. Swain, Carolyn Taylor, Andrew Tutt, Pinuccia Valagussa, Cornelis J.�H. van de Velde, Jos A. van der Hage, Giuseppe Viale, Gϋnter von Minckwitz and 10 more - The Lancet Oncology 2017 cited by 1,133

  11. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

    Authors: , , , , - Pharmacological Reviews 2004 cited by 3,728

  12. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Adilson Faccio, Andrea Moretto, Nils Gunnar Skare, Jamille Dutra, Luciana Viola, Karina Vianna, Fernando Meton, Cláudia Vaz de Melo Sette, Amanda Faulhaber, Vincent C. Tam, Félix Couture, Jim Biagi, Hélène Castel, Karen Mulder, Yoo‐Joung Ko, Kevin Zbuk, Stephen Welch, Annie Beaudoin, Alexandra Heurgué, Éric Assenat, Isabelle Archambeaud, David Tougeron, Jean‐Marie Péron, Marine Gilabert, Jean–Pierre Bronowicki, Stéphane Cattan, Jean‐Frédéric Blanc, Mohamed Bouattour, Jean–Marc Phelip, Valérie Boige, Pierre Michel, Anne-Claire Frin, Enrico N. De Toni, Marie‐Luise Berres, Arndt Vogel, Thomas Berg, Thomas J. Ettrich, Dirk Waldschmidt, H. Wedemeyer, Marcus‐Alexander Wörns, Michael Bitzer, Karl-Heinz Weiss, George Lau, Stephen L. Chan, Thomas Yau, Y. Tai, Ann Shing Lee, Satheesh Chiradoni Thungappa, Lokesh K. N, Vikas Sureshchand Ostwal, Kattimani Kiran Ashok, Sushant Mittal, Hari Om Goyal, Sankar Srinivasan, Ghanashyam Biswas, Mallavarapu Mohan, Sewanti Limaye, Nirav Asarawala, Lorenza Rimassa, Alfredo Falcone, Luca Gianni, Antonio Gasbarrini, Bruno Daniele, Antonio Avallone, Giovanni Luca Frassineti, Fausto Roila, Masatoshi Kudo, Tomokazu Kawaoka, Manabu Morimoto, Yasuhiro Takikawa and 103 more - Annals of Oncology 2024 cited by 312

  13. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mirko Dolci, Richard D. Gelber - New England Journal of Medicine 2005 cited by 5,098

  14. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

    Authors: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2022 cited by 386

  15. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , - The Lancet Oncology 2017 cited by 656

  16. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli and 127 more - The Lancet Oncology 2020 cited by 498

  17. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

    Authors: , , , , , , , , , , , , , , , , , - The Lancet 2017 cited by 1,041

  18. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 cited by 874

  19. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jon Godwin, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Yaochen Wang, John Crown, Evandro de Azambuja, Suzette Delaloge, Helena Fung, Charles E. Geyer, M. Spielmann, Pinuccia Valagussa, Kathy S. Albain, Stewart Anderson, R. Arriagada, John Bartlett, Elizabeth Bergsten-Nordström, Judith M. Bliss, Étienne Brain, Lisa Carey, Robert E. Coleman, Jack Cuzick, Nancy E. Davidson, Lucia Del Mastro, Angelo Di Leo, James J. Dignam, Mitch Dowsett, Bent Ejlertsen, Prue Francis, Michael Gnant, Matthew Bidwell Goetz, Pam Goodwin, Pat Halpin-Murphy, Daniel Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P. Mamounas, Miguel Martín, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Lori J. Pierce, Philip Poortmans, Vinod Raina, Daniel Rea, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Tanja Španić, Joseph A. Sparano, Guenther G. Steger, Gong Tang, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Xiang Wang, Timothy J. Whelan, Nicholas Wilcken, Norman Wolmark, David Cameron, Jonas Bergh, Kathleen I. Pritchard and 1 more - The Lancet Oncology 2021 cited by 348

  20. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2024 cited by 153

  21. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet 2010 cited by 1,268

  22. Treatment of HER2-positive breast cancer: current status and future perspectives

    Authors: , , , , , - Nature Reviews Clinical Oncology 2011 cited by 871

  23. Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michele Reni, Richard A. Epstein, Paul L. Vasey, Jeremy Shapiro, Matthew Burge, Yu Jo Chua, Marion Harris, Nick Pavlakis, Niall C. Tebbutt, Gerald W. Prager, Christian Dittrich, Friedrich Längle, Kathrin Philipp‐Abbrederis, Richard Greil, Herbert Stöger, Michael Girschikofsky, Thomas Kuehr, Jean–Luc Van Laethem, Stéphanie Laurent, Neesha C. Dhani, Yoo Joung Ko, Scot Dowden, Petr Kavan, Mustapha Édouard Tehfe, Eugen Kubala, Milan Kohoutek, Per Pfeiffer, Mette Yilmaz, Vibeke K. Parner, Tapio Salminen, Leena‐Maija Soveri, Eija Korkeila, Pia Österlund, Julien Taı̈eb, David Tougeron, Pascal Artru, François‐Xavier Caroli‐Bosc, Rosine Guimbaud, Antony Turpin, Thomas Walter, Jean‐Baptiste Bachet, Volker Kunzmann, Florian Kreth, Andreas De Block, Marino Venerito, Helmut Oettle, Meinolf Karthaus, Jörg Trojan, Gunnar Folprecht, Markus M. Lerch, Frank Kullmann, Marcel Reiser, Volker Heinemann, Marcus‐Alexander Wörns, H. Schulz, Benjamin Garlipp, Thomas Yau, Lam Stephen Chan, Balázs Juhász, László Landherr, Tamás Pintér, G. Bodoky, Zsuzsanna Kahán, Raymond McDermott, Derek G. Power, Luca Gianni, Salvatore Siena, Michèle Milella, Alfredo Falcone, Rossana Berardi and 87 more - Journal of Clinical Oncology 2022 cited by 132

  24. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

    Authors: , , , , , , , , , , , , , , , , , - npj Breast Cancer 2022 cited by 103